FDA accepts new drug application and grants priority review for TLX101-CDx brain cancer imaging agent
October 24, 2024 | 05:02
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has accepted the new drug application for TLX101-CDx.
Mobile Version